Audit of screen failure in 15 randomised studies from a low and middle-income country

Background Growth and development in patient management occurs via randomised studies. Screen failure is a significant hurdle while conducting randomised studies. There is limited data available from low and middle-income countries about factors resulting in screen failure. Hence, this audit was performed to identify the proportion of patients who screen failed and to elucidate reasons for the same. Methods This was an audit of 15 randomised studies performed by medical oncology solid tumour unit II of Tata Memorial Centre. The screening logs of these studies were acquired. From the screening logs, data regarding the number of patients who had screen failed & reason for the same were obtained. Descriptive statistics were performed. Results A total of 7,481 patients were screened for 15 randomised clinical studies. Out of these, 3,666 (49.0%) patients were enrolled into trials and 3,815 (51.0%) screen failed. The most common reason for screen failure was ‘not meeting inclusion criteria’ (54.9%) followed by declining to take treatment (22.2%). Other factors that affect enrolment were ‘not willing to stay in the locality of the trial site’ (6.2%), being recruited in other studies (3.7%), poor performance status (PS) (3.4%), non-compliance (2.2%), meeting exclusion criteria (0.9%) and ‘other’ (6.5%). Conclusion The commonest causes of screen failure in lower and middle-income countries are non-meeting of inclusion criteria followed by declining to take treatment, not willing to stay in locality of trial site, recruited into other studies, poor PS, non-compliance, meeting exclusion criteria & ‘other’. This information would help analysing and hence planning of newer strategies to decrease the rate of screen failure.

[1]  J. Czernin,et al.  Outcome of Patients with PSMA PET/CT Screen Failure by VISION Criteria and Treated with 177Lu-PSMA Therapy: A Multicenter Retrospective Analysis , 2022, The Journal of Nuclear Medicine.

[2]  V. Perkovic,et al.  Impact of random variation in albuminuria and estimated glomerular filtration rate on patient enrolment and duration of clinical trials in nephrology , 2022, Diabetes, obesity & metabolism.

[3]  M. Aliyu,et al.  Strategies for Successful Clinical Trial Recruitment of People Living with HIV in Low- and Middle-Income Countries: Lessons Learned and Implementation Implications from the Nigeria Renal Risk Reduction (R3) Trial , 2021, Current HIV/AIDS Reports.

[4]  Brian C. Case,et al.  Reasons for Screen Failure for Transcatheter Mitral Valve Repair and Replacement. , 2021, The American journal of cardiology.

[5]  C. Patten,et al.  The Role of Social Media in Enhancing Clinical Trial Recruitment: Scoping Review , 2020, Journal of medical Internet research.

[6]  S. Wong,et al.  Recruitment and adherence of randomized controlled trials for mild cognitive impairment: A systematic review and meta‐analysis , 2020, International journal of geriatric psychiatry.

[7]  N. Gogtay,et al.  Factors influencing recruitment and retention of participants in clinical studies conducted at a tertiary referral center: A five-year audit , 2020, Perspectives in clinical research.

[8]  T. John,et al.  Effect of Reasons for Screen Failure on Subsequent Treatment Outcomes in Cancer Patients Assessed for Clinical Trials , 2019, Oncology.

[9]  L. Malik,et al.  Eligibility criteria for phase I clinical trials: tight vs loose? , 2019, Cancer Chemotherapy and Pharmacology.

[10]  N. Foster,et al.  Neuropsychological, Psychiatric, and Functional Correlates of Clinical Trial Enrollment , 2019, The Journal of Prevention of Alzheimer's Disease.

[11]  Thomas D. Scott,et al.  High screen failure rate in patients with resistant hypertension: Findings from SYMPLICITY HTN-3. , 2017, American heart journal.

[12]  R. Conwit,et al.  Screen failure data in clinical trials: Are screening logs worth it? , 2014, Clinical trials.